Dimethyl fumarate controlled-release - Forward Pharma

Drug Profile

Dimethyl fumarate controlled-release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • No development reported Multiple sclerosis

Most Recent Events

  • 18 Apr 2017 Forward Pharma intends to challenge the decision by the PTAB in the patent interference lawsuit filed by Forward Pharma related to oral administration of dimethyl fumarate 480mg for Multiple sclerosis in USA
  • 31 Mar 2017 The PTAB issued a decision in favour of Biogen in the patent interference lawsuit filed by Forward Pharma related to oral administration of dimethyl fumarate 480mg for Multiple sclerosis in USA
  • 17 Jan 2017 Forward Pharma enters into a settlement and license agreement with Biogen related to oral administration of dimethyl fumarate 480mg for multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top